Source: Eur Respir J 2011; 37: 484-485



Rating:

Share or cite this content

Citations should be made in the following way:
Handoko M.L., de Man F.S., Vonk-Noordegraaf A.. The rise and fall of endothelin receptor antagonists in congestive heart failure. Eur Respir J 2011; 37: 484-485

Member's Comments

No comment yet.

Related content which might interest you: Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension Source: Eur Respir J 2015; 46: 283-286 Year: 2015 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Effect of adaptive servo-ventilation on plasma endothelin-1 levels in patients with congestive heart failure and Cheyne-Strokes respiration Source: Eur Respir J 2005; 26: Suppl. 49, 37s Year: 2005 Theophylline increases muscle sympathetic activity in patients with congestive heart failure Source: Annual Congress 2003 - Management of sleep related breathing disorders Year: 2003 Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 Beta blockers in heart failure and airways disease Source: Annual Congress 2010 - Comorbidity in obstructive airway disease Year: 2010 Endothelin: setting the scene in PAH Source: Eur Respir Rev 2008; 17: 3-7 Year: 2007 The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension (PAH) associated with congenital heart defects (CHD) Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007 Are beta-blockers able to prevent sleep apnoea in congestive heart failure? Source: Breathe 2008; 5: 76 Year: 2008 Adrenergic receptor blocker reverses cardiac metabolic remodeling and improves right ventricular function in experimental pulmonary hypertension Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease Year: 2011 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Effect of acute beta-blocker withholding on the ventilatory efficiency in patients with advanced chronic congestive heart failure Source: Annual Congress 2009 - Novel insights in exercise physiology from cells to humans Year: 2009 Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Single centre experience with endothelin receptor blockade in pulmonary hypertension Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Impact of beta-blockers on sleep-disoredered breathing in chronic heart failure Source: Eur Respir J 2007; 30: Suppl. 51, 509s Year: 2007 Inhalation of endothelin receptor blockers in pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Long-term monitoring of respiratory function and influence of selective beta blockers on its decline in COPD patients with concomitant coronary heart disease Source: Eur Respir J 2001; 18: Suppl. 33, 25s Year: 2001